Upcycling plastic waste toward sustainable energy storage

What if you could solve two of Earth’s biggest problems in one stroke? UC Riverside engineers have developed a way to recycle plastic waste, such as soda or water bottles, into a nanomaterial useful for energy storage.

Mihri and Cengiz Ozkan and their students have been working for years on creating improved energy storage materials from sustainable sources, such as glass bottles, beach sand, Silly Putty, and portabella mushrooms. Their latest success could reduce plastic pollution and hasten the transition to 100% clean energy.

“Thirty percent of the global car fleet is expected to be electric by 2040, and high cost of raw battery materials is a challenge,” said Mihri Ozkan, a professor of electrical engineering in UCR’s Marlan and Rosemary Bourns College of Engineering. “Using waste from landfill and upcycling plastic bottles could lower the total cost of batteries while making the battery production sustainable on top of eliminating plastic pollution worldwide.”

In an open-access article published in Energy Storage, the researchers describe a sustainable, straightforward process for upcycling polyethylene terephthalate plastic waste, or PET, found in soda bottles and many other consumer products, into a porous carbon nanostructure.

They first dissolved pieces of PET plastic bottles in a solvent. Then, using a process called electrospinning, they fabricated microscopic fibers from the polymer and carbonized the plastic threads in a furnace. After mixing with a binder and a conductive agent, the material was then dried and assembled into an electric double-layer supercapacitor within a coin-cell type format.

When tested in the supercapacitor, the material contained the characteristics of both a double-layer capacitor formed by the arrangement of separated ionic and electronic charges, as well as redox reaction pseudo-capacitance that occurs when the ions are electrochemically absorbed onto surfaces of materials.

Though they don’t store as much energy as lithium-ion batteries, these supercapacitors can charge much faster, making batteries based on plastic waste a good option for many applications.

By “doping” the electrospun fibers prior to carbonization with various chemicals and minerals such as boron, nitrogen, and phosphorus, the team plans to tune the final material to have improved electrical properties.

“At UCR, we have taken the first steps toward recycling plastic waste into a rechargeable energy storage device,” said doctoral student and first author Arash Mirjalili. “We believe that this work has environmental and economic advantages and our approach can present opportunities for future research and development.”

The authors believe the process is scalable and marketable, and that it represents major progress toward keeping waste PET out of landfills and the oceans.

“The upcycling of PET plastic waste for energy storage applications could be considered the holy grail for green manufacturing of electrode materials from sustainable waste sources,” said mechanical engineering professor Cengiz Ozkan. “This demonstration of a new class of electrodes in the making of supercapacitors will be followed by a new generation of Li-ion batteries in the future, so stay tuned.”

Story Source:

Materials provided by University of California – Riverside. Original written by Holly Ober. Note: Content may be edited for style and length.

Share Button

Cosmetic surgeon struck off after botched ops

Patients awarded thousands in compensation have not been paid as he did not have insurance.

Share Button

Training and Performance

In many jobs your working hours are performance hours. You’re expected to do the work that creates value. If you’re a programmer, you get paid to program. If you’re a lawyer, you get paid to help people solve legal problems.

But in some jobs, performance is just a small slice of paid time on the job.

Consider a professional basketball player, for instance. The performance time is during competitive games with other teams. Game time performance is what creates the value for the franchise, the fans, the sponsors, and the other stakeholders.

But for the athletes, most of the time on the job isn’t performance time. During those other hours, they’re training, practicing, being coached, preparing, recovering, etc. Of course this is still important work so they can be prepared to perform well during televised games.

What if you currently do work that’s mostly performance but you approach it like a professional athlete? What would that look like?

Where is your job closest to the performance of a pro athlete? Which activities really count in terms of delivering value and earning your pay?

Most likely your hours on the job aren’t all equal in terms of delivering value. Some activities may be more critical than others, especially when it comes to career advancement or business success.

Do you know what those critical activities are?

Once you know the critical activities, where’s the training portion of your day? Where’s the ongoing investment in further honing your skills, so you can get better and better at the performance side? Are you investing in enough training… or barely any?

I could frame blogging as a performance activity since my articles are public facing and provide value to people. I could then imagine many hours of private journaling, reading, experimenting, and exploring to be training and practice.

Alternatively, I could frame blogging as a practice or training activity. And I could imagine a larger project like writing a book, creating a course, or delivering a workshop as a performance activity.

The reality is that I use both frames and often flip between them. Sometimes I see blogging as a way to beta-test ideas. Other times I see it as a core activity for delivering value to people. The framing is flexible. But what isn’t so flexible is that some form of training and practice is necessary. Whichever frame I use, training and practice must be an essential part of it.

Alternatively, suppose you view your work as 100% performance time. There is no practice and training while you’re on the clock. How does that framing sit with you? Does it suggest that if you want to improve, you have to devote some of your personal unpaid time to training and skill-building? I think that’s exactly what it suggests.

While you do get some performance gains from training, it’s best not to confuse the two. Training gives you more coverage of different skills than performance alone ever will. You may practice situations in training that you’ll rarely experience on the performance side, yet it’s critical to have those skills when they’re needed. With training you can also break down the fundamental skills and work on them more thoroughly than you can on the performance side.

Imagine that 90% (or more) of your work time is just practice and training, and 10% (or less) is real performance time. If you use this lens, which activities would you put on each side?

What are your most critical skills that provide the most value? What would happen if you devoted the other 90% of your work time to honing and training up those skills to an even higher level?

Suppose you create and publish videos as your main work product. All the value you provide is in your published videos. Now suppose you spent 90% of your work time just training and practicing your video skills – but not publishing any of that work. Do you think that would impact what you’re able to deliver with the other 10%?

The 90-10 ratios are arbitrary by the way. You could use 80-20, 50-50, or anything else that appeals to you. What ratios make you reconsider your approach to work? I like the extreme of 90-10 thinking because it gets me closer to the mindset of a pro athlete who has to invest an extraordinary amount of training and practice time for a small amount of performance time. In reality their ratio is likely to be even more extreme than 90-10, especially if you consider Olympic athletes who may train years for a single performance (which in some cases may be measured in seconds).

Play around with this frame. You don’t have to use it exclusively, but it can be an interesting way to think about work and productivity. What if you approached your work like a pro athlete whereby the vast majority of your work time was treated as training and practice for a small but important slice of critical performance time? Could this (or something close to it) be a better model than seeing your work at 100% performance time?

Share Button

Health24.com | Antiviral drugs tied to heart issue in Covid-19 patients

  • Two common antiretroviral drugs given to Covid-19 patients can cause bradycardia, a serious slowing of the heart
  • These drugs had been considered a promising treatment for Covid -19
  • Going forward, the experimental antiviral drug remdesivir appears to be a much more effective alternative 

Older, critically ill Covid-19 patients who are given a combination of two common antiretroviral drugs can experience a drastic slowing of their heart rate, French researchers report.

In their study of 41 patients treated with lopinavir and ritonavir twice daily for 10 days, 22% developed a slow heart rate condition called bradycardia. When the drugs were stopped or doses lowered, the patients’ heart rates returned to normal, according to the team from Amiens University Hospital, in France.

“There are extensive investigations underway to find therapies that are effective at treating patients infected with Covid-19,” said Dr Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, who had no part in the study.

Potential for bradycardia

The lopinavir-ritonavir combo had been considered a promising treatment for Covid-19 based on very small reports, randomised clinical trials and off-label use, Fonarow said.

But earlier studies have suggested that this combination may also lead to heart block, a problem with electrical signals in the heart. “Determining how these drugs lead to the bradycardia will require further study,” Fonarow said.

Doctors prescribing these drugs should be aware of the potential for bradycardia and carefully monitor patients, he added.

“Moreover, preliminary clinical trial results suggest this therapy is not effective in Covid-19, so use in this setting will likely be very limited going forward,” Fonarow said.

Lopinavir and ritonavir have also been used to treat other viruses, including SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome) and HIV. The researchers noted that bradycardia has also been seen among HIV patients treated with the drugs.

Normally, adults’ hearts beat between 60 and 100 times a minute. In bradycardia, the rate falls below 60 beats per minute, causing decreased blood flow that can lead to fainting, chest pain, low blood pressure and heart failure.

Combo not well tolerated

Patients in the French study who developed the problem were older than ones who did not, averaging 62 to 80 years of age, the researchers reported.

Dr Marc Siegel, a professor of medicine at NYU Langone Medical Center in New York City who reviewed the findings, noted that the two-drug combo had not helped hospitalised Covid-19 patients in other recent trials.

Siegel said the treatment should not be used with Covid-19 because it’s not effective in either critically ill patients or in the early stages of the disease.

“The remaining hope for this combination of drugs was early in the disease, but the significant amount of bradycardia in these critically ill patients raises the question that this combo is not well tolerated in many patients,” he said.

Going forward, Siegel said, the experimental antiviral drug remdesivir appears to be effective and is already being used to fight Covid-19.

The new study, by Dr Christophe Beyls and colleagues, was published early in 9 July  in the journal Circulation: Arrhythmia and Electrophysiology.

Image credit:

Share Button

Health24.com | Scientists find source of Covid-19 clots

  • Many Covid-19 patients present with blood clots that can be deadly
  • These blood clots are linked to the endothelial cells that line the inside of blood vessels 
  • Researchers are trying to find strategies to safeguard the endothelial layer and prevent blood clots from forming

Covid-19 is linked to potentially fatal blood clots. Researchers now believe they’ve found out how they occur, which potentially could lead to better treatment.

“While many forms of illness can generate blood clots, the endothelial cells that line the inside of blood vessels play a surprisingly large role in Covid-19 clotting,” said researcher Dr Alfred Lee, an associate professor of medicine at Yale Cancer Center.

“Endothelial damage is a central component in the entire spectrum of Covid-19 disease. Our study is the first to demonstrate that this process of endothelial damage is present in a wide range of Covid-19 patients, particularly as people become critically ill,” Lee said in a Yale news release.

For the study, Lee and his team examined the blood of 68 patients with Covid-19. Of these patients, 48 were critically ill in an ICU. The other 20 were hospitalised but not in the ICU.

Therapeutic strategies

The researchers found that some markers of endothelial cell and blood platelet activation were nearly twice as high in the ICU patients compared to those not in the ICU.

One marker, called thrombomodulin, was linked with survival among all patients. Measuring thrombomodulin might help doctors better treat patients, the researchers say.

“If we have a marker to identify which patients are most likely to progress towards critical illness and possibly death, that would be hugely helpful, as these patients might benefit from closer monitoring and possibly earlier intervention,” Lee said.

Study co-author Dr Hyung Chun is trying to develop a test based on thrombomodulin, which is elevated in other life-threatening diseases as well.

“The other goal we’re pursuing in parallel is to find therapeutic strategies that could safeguard the endothelial layer and may prevent the blood clots from forming,” said Chun, an associate professor of medicine and pathology at Yale School of Medicine. “Are there approved drugs we could potentially repurpose for this context?”

One possible candidate is the drug dipyridamole, used to prevent stroke.

The report was published late in June in the journal The Lancet Haematology.

Image credit:

Share Button

Coronavirus: Exposure rate ‘similar’ in London and Stockholm

Antibody tests suggest similar exposure to the virus in the two capitals, despite different strategies.

Share Button

Coronavirus: Severe mental health problems rise amid pandemic

An NHS Confederation report predicts a 20% increase in demand for services in the coming months.

Share Button

Take headache relief into your own hands

Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.

Advertising & Sponsorship

Mayo Clinic Marketplace

Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.

Share Button

Research exposes new vulnerability for SARS-CoV-2

Northwestern University researchers have uncovered a new vulnerability in the novel coronavirus’ infamous spike protein — illuminating a relatively simple, potential treatment pathway.

The spike protein contains the virus’ binding site, which adheres to host cells and enables the virus to enter and infect the body. Using nanometer-level simulations, the researchers discovered a positively charged site (known as the polybasic cleavage site) located 10 nanometers from the actual binding site on the spike protein. The positively charged site allows strong bonding between the virus protein and the negatively charged human-cell receptors.

Leveraging this discovery, the researchers designed a negatively charged molecule to bind to the positively charged cleavage site. Blocking this site inhibits the virus from bonding to the host cell.

“Our work indicates that blocking this cleavage site may act as a viable prophylactic treatment that decreases the virus’ ability to infect humans,” said Northwestern’s Monica Olvera de la Cruz, who led the work. “Our results explain experimental studies showing that mutations of the SARS-CoV-2 spike protein affected the virus transmissibility.”

The research was published online last week in the journal ACS Nano.

Olvera de la Cruz is the Lawyer Taylor Professor of Materials Science and Engineering in Northwestern’s McCormick School of Engineering. Baofu Qiao, a research assistant professor in Olvera de la Cruz’s research group, is the paper’s first author.

Made up of amino acids, SARS-CoV-2’s polybasic cleavage sites have remained elusive since the COVID-19 outbreak began. But previous research indicates that these mysterious sites are essential for virulence and transmission. Olvera de la Cruz and Qiao discovered that polybasic cleavage site is located 10 nanometers from human cell receptors — a finding that provided unexpected insight.

“We didn’t expect to see electrostatic interactions at 10 nanometers,” Qiao said. “In physiological conditions, all electrostatic interactions no longer occur at distances longer than 1 nanometer.”

“The function of the polybasic cleavage site has remained elusive,” Olvera de la Cruz said. “However, it appears to be cleaved by an enzyme (furin) that is abundant in lungs, which suggests the cleavage site is crucial for virus entry into human cells.”

With this new information, Olvera de la Cruz and Qiao next plan to work with Northwestern chemists and pharmacologists to design a new drug that could bind to the spike protein.

The research, “Enhanced binding of SARS-CoV-2 spike protein to receptor by distal polybasic cleavage sites,” was supported by the U.S. Department of Energy (award number DE-FG02-08ER46539), the Sherman Fairchild Foundation and the Center for Computation and Theory of Soft Materials at Northwestern University.

Story Source:

Materials provided by Northwestern University. Original written by Amanda Morris. Note: Content may be edited for style and length.

Share Button

Pasteurization inactivates COVID-19 virus in human milk: new research

A team of medical researchers has found that in human milk, pasteurisation inactivates the virus that causes COVID-19, confirming milk bank processes have been safe throughout the pandemic, and will remain safe going forward, too.

The study — published this month in the Journal of Paediatrics and Child Health — was a partnership between UNSW and a multidisciplinary team from Australian Red Cross Lifeblood Milk.

There are five human milk banks in Australia. As the COVID-19 pandemic evolves, these milk banks continue to provide donated breast milk to preterm babies who lack access to their mother’s own milk. Donors are screened for diseases, and milk is tested and pasteurised to ensure that it is safe for medically fragile babies.

“While there is no evidence that the virus can be transmitted through breast milk, there is always a theoretical risk,” says Greg Walker, lead author and PhD candidate in Professor Bill Rawlinson’s group at UNSW Medicine.

“We’ve seen in previous pandemics that pasteurised donor human milk (PDHM) supplies may be interrupted because of safety considerations, so that’s why we wanted to show that PDHM remains safe.”

For this study, the team worked in the Kirby Institute’s PC3 lab to experimentally infect small amounts of frozen and freshly expressed breast milk from healthy Lifeblood Milk donors.

“We then heated the milk samples — now infected with SARS-CoV-2 — to 63?C for 30 minutes to simulate the pasteurisation process that occurs in milk banks, and found that after this process, they did not contain any infectious, live virus,” Mr Walker says.

“Our findings demonstrate that the SARS-CoV-2 virus can be effectively inactivated by pasteurisation.”

The researchers say their experiments simulated a theoretical worst-case scenario.

“The amount of virus we use in the lab is a lot higher than what would be found in breast milk from women who have COVID-19 — so we can be really confident in these findings,” Mr Walker says.

Dr Laura Klein, Research Fellow and Lifeblood Milk senior study author, explains that the purpose of the research was to provide evidence behind what people already expected.

“Pasteurisation is well known to inactivate many viruses, including the coronaviruses that cause SARS and MERS,” she says.

“These findings are also consistent with a recent study that reported SARS-CoV-2 is inactivated by heat treatment in some contexts.”

Kirby Institute researcher and study co-author, Associate Professor Stuart Turville, says this work was a first.

“We’ve been working in real time to grow and make tools against this new pathogen, which has been an exponential learning curve for everyone involved. This work and many others that are continuing in the PC3 lab tell us how we can be safe at the front line working with this virus in the real world.”

Cold storage doesn’t inactivate the virus

The researchers also tested if storing SARS-CoV-2 in human milk at 4°C or -30°C would inactivate the virus — the first time a study has assessed the stability of experimentally infected SARS-CoV-2 in human milk under common storage conditions.

“We found that cold storage did not significantly impact infectious viral load over a 48-hour period,” Mr Walker says.

“While freezing the milk resulted in a slight reduction in the virus present, we still recovered viable virus after 48 hours of storage.”

The researchers say the fact that SARS-CoV-2 was stable in refrigerated or frozen human milk could help inform guidelines around safe expressing and storing of milk from COVID-19 infected mothers.

“For example, we now know that it is particularly important for mothers with COVID-19 to ensure their expressed breast milk does not become contaminated with SARS-CoV-2,” Dr Klein says.

“But it’s also important to note that breastfeeding is still safe for mothers with COVID-19 — there is no evidence to suggest that SARS-CoV-2 can be transmitted through breastmilk.”

Donated breast milk is recommended by the World Health Organisation when mother’s own milk is not available to reduce the risks of some health challenges premature babies can face. Lifeblood Milk has provided donor milk to over 1500 babies born premature in 11 NICUs across New South Wales, South Australia, and Queensland since launching in 2018.

Share Button